Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"image","alt":"Creative Medical Technology Holdings, Inc.","displaySize":"","headline":null,"caption":"Creative Medical Technology Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":43,"url":"https://media.zenfs.com/en/globenewswire.com/4f20fc41994fc07ca8de61005b80d4fe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/j6O8qxQI9Xl006odrRFm5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYw/https://media.zenfs.com/en/globenewswire.com/4f20fc41994fc07ca8de61005b80d4fe","width":300,"height":43}},"lazy":false},{"type":"text","content":"Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market","length":149,"tagName":"p"},{"type":"text","content":"PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.","length":377,"tagName":"p"},{"type":"text","content":"The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse events reported.","length":233,"tagName":"p"},{"type":"text","content":"Ultrasome™ is derived from the Company’s GMP-manufactured cell therapy product CELZ-201 (Olastrocel), which is currently being evaluated in the Company’s FDA-cleared ADAPT clinical trial. This relationship establishes a direct connection between CELZ’s clinical-stage biologic platform and its next-generation cell-free regenerative strategy, expanding the potential applications of CELZ-201 into broader, high-volume indications.","length":430,"tagName":"p"},{"type":"text","content":"Platform Expansion: Extending CELZ-201 into Cell-Free Regenerative Therapies with Ultrasome™","length":92,"tagName":"p"},{"type":"text","content":"Creative Medical is leveraging the biological signaling components of CELZ-201 in a cell-free format, enabling scalable manufacturing, reduced cost of production, off-the-shelf availability, and simplified execution across outpatient settings. Ultr...

More updates from Creative Medical Technology Holdings, Inc.